公开(公告)号：US10752695B2

公开(公告)日：2020-08-25

申请号：US15197496

申请日：2016-06-29

Applicant: GENMAB A/S

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschoten

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K51/10 ,  A61K47/68 ,  C07K16/16 ,  C07K16/18 ,  C07K1/00 ,  A61K39/00

Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

公开(公告)号：US20130345406A1

公开(公告)日：2013-12-26

申请号：US13912581

申请日：2013-06-07

Applicant: Genmab A/S

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschoten

IPC: C07K16/18 ,  C07K16/16

CPC classification number: C07K16/2887 ,  A61K47/6803 ,  A61K47/6813 ,  A61K47/6835 ,  A61K47/6839 ,  A61K47/6845 ,  A61K47/6849 ,  A61K51/10 ,  A61K51/1006 ,  A61K51/1021 ,  A61K51/1027 ,  A61K51/103 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/16 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。